Acurx Enrolls First Patient in PATHFINDER Trial for Recurrent C. difficile
ACXP is trading near its 52-week low of $1.305 (8.2% above the low).
Summary
Acurx has enrolled the first patient in its PATHFINDER Phase 2 trial of ibezapolstat for multiply-recurrent C. difficile infection. The trial is fully funded and will enroll approximately 20 patients, with data intended to support an NDA filing based on a single Phase 3 trial. This follows FDA meeting minutes from August indicating a potential streamlined approval path. The company remains subject to a going concern warning, but this milestone advances its lead asset toward registration.
At the time of this announcement, ACXP was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $1.31 to $8.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.